Page 51 - Noble-Virtual-Healthcare-2024

Unicycive Therapeutics, Inc.

SELECTED FINANCIAL ITEMS UNCY

(in millions of USD)
CQ1 '23 CQ2 '23 CQ3 '23 CQ4 '23 LTM
Income Statement Key Items
Total Revenue 0.68 NA NA 0.00 0.68
Gross Profit 0.68 NA NA 0.00 0.68
Gross Margin 100% NM NM NM 100%
EBIT (4.20) (4.32) (5.94) (6.31) (20.78)
EBIT Margin -623% NM NM NM -3078%
Net Income to Common Shareholders (14.58) (3.84) (4.33) (7.80) (30.54)
Net Margin -2159% NM NM NM -4525%

Balance Sheet Key Items
Total Assets 27.20 22.88 19.44 14.19 14.19
Cash & Short Term Investments 24.33 18.82 14.35 9.70 9.70
% of Assets 89% 82% 74% 68% 68%
Current Assets -Total 26.18 21.93 18.57 13.40 13.40
% of Assets 96% 96% 96% 94% 94%
Total Liabilities 16.69 16.05 16.01 18.00 18.00
% of Assets 61% 70% 82% 127% 127%
Current Liabilities - Total 15.97 15.42 15.46 17.53 17.53
% of Assets 59% 67% 79% 124% 124%
Long Term Debt NA NA NA NA NA
% of Assets NM NM NM NM NM
Total Equity 10.52 6.83 3.43 (3.81) (3.81)
% of Assets 39% 30% 18% -27% -27%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (3.92) (5.50) (4.42) (4.44) (18.28)
Net Cash Flow - Investing NA (0.01) 0.00 0.00 (0.01)
Net Cash Flow - Financing 27.80 0.00 (0.05) (0.21) 27.54

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Nineteenth Annual Small & Microcap Investor Conference